Benmoxin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Benmoxin
Accession Number
DB09246
Type
Small Molecule
Groups
Withdrawn
Description

Benmoxin is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine class. It was synthesized in 1967 and was subsequently used as an antidepressant in Europe, but is now no longer marketed.

Structure
Thumb
Synonyms
  • Mebamoxine
International/Other Brands
Nerusil / Neuralex
Categories
UNII
XC9FY2SGBG
CAS number
7654-03-7
Weight
Average: 240.306
Monoisotopic: 240.126263143
Chemical Formula
C15H16N2O
InChI Key
BEWNZPMDJIGBED-UHFFFAOYSA-N
InChI
InChI=1S/C15H16N2O/c1-12(13-8-4-2-5-9-13)16-17-15(18)14-10-6-3-7-11-14/h2-12,16H,1H3,(H,17,18)
IUPAC Name
N'-(1-phenylethyl)benzohydrazide
SMILES
CC(NNC(=O)C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of depression.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineBenmoxin may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineBenmoxin may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineBenmoxin may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Benmoxin.Experimental
AcarboseBenmoxin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololBenmoxin may increase the hypotensive activities of Acebutolol.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Benmoxin.Experimental
AlbiglutideBenmoxin may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Benmoxin.Approved, Illicit
AliskirenBenmoxin may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Benmoxin.Approved, Investigational
AlogliptinBenmoxin may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Benmoxin.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Benmoxin.Illicit
AlprenololBenmoxin may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Benmoxin.Approved
AmbrisentanBenmoxin may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineBenmoxin may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineBenmoxin may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineBenmoxin may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Amoxapine.Approved
AmphetamineBenmoxin may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Benmoxin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Arformoterol.Approved, Investigational
AtenololBenmoxin may increase the hypotensive activities of Atenolol.Approved
AtomoxetineBenmoxin may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineBenmoxin may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Bambuterol.Approved, Investigational
BenazeprilBenmoxin may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideBenmoxin may increase the hypotensive activities of Bendroflumethiazide.Approved
BenzphetamineBenmoxin may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilBenmoxin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Benmoxin.Approved
BetaxololBenmoxin may increase the hypotensive activities of Betaxolol.Approved
BethanidineBenmoxin may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Benmoxin is combined with Bezafibrate.Approved
BietaserpineBenmoxin may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostBenmoxin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBenmoxin may increase the hypotensive activities of Bisoprolol.Approved
BosentanBenmoxin may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Benmoxin may increase the hypotensive activities of BQ-123.Investigational
BretyliumBenmoxin may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Brimonidine.Approved
BrofaromineBrofaromine may increase the hypertensive activities of Benmoxin.Experimental
BromocriptineBenmoxin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BupranololBenmoxin may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Benmoxin.Approved, Illicit, Investigational, Vet Approved
BupropionBenmoxin may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Benmoxin.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Benmoxin.Approved, Illicit, Vet Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Benmoxin.Approved
CadralazineBenmoxin may increase the hypotensive activities of Cadralazine.Experimental
CafedrineBenmoxin may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinBenmoxin may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanBenmoxin may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilBenmoxin may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilBenmoxin may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilBenmoxin may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Benmoxin.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Benmoxin.Illicit, Investigational, Vet Approved
CaroxazoneBenmoxin may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololBenmoxin may increase the hypotensive activities of Carteolol.Approved
CarvedilolBenmoxin may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololBenmoxin may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideBenmoxin may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineBenmoxin may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamideBenmoxin may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneBenmoxin may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineBenmoxin may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilBenmoxin may increase the hypotensive activities of Cilazapril.Approved
CirazolineBenmoxin may increase the hypertensive activities of Cirazoline.Experimental
CitalopramBenmoxin may increase the serotonergic activities of Citalopram.Approved
ClemastineBenmoxin may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineBenmoxin may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidineBenmoxin may increase the hypotensive activities of Clonidine.Approved
CloranololBenmoxin may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Benmoxin.Approved, Illicit
CryptenamineBenmoxin may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Benmoxin.Approved
CyclopenthiazideBenmoxin may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideBenmoxin may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineBenmoxin may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinBenmoxin may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineBenmoxin may increase the serotonergic activities of Dapoxetine.Investigational
DebrisoquinBenmoxin may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilBenmoxin may increase the hypotensive activities of Delapril.Experimental
DeserpidineBenmoxin may increase the hypotensive activities of Deserpidine.Approved
DesipramineBenmoxin may increase the serotonergic activities of Desipramine.Approved
DesvenlafaxineBenmoxin may increase the serotonergic activities of Desvenlafaxine.Approved
DexmethylphenidateBenmoxin may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineBenmoxin may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanBenmoxin may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Benmoxin.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Benmoxin.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Benmoxin.Approved, Investigational
DiazoxideBenmoxin may increase the hypotensive activities of Diazoxide.Approved
DibenzepinBenmoxin may increase the serotonergic activities of Dibenzepin.Experimental
diethylnorspermineBenmoxin may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionBenmoxin may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineBenmoxin may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Benmoxin.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Benmoxin.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Benmoxin.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Benmoxin.Experimental, Illicit
DiltiazemBenmoxin may increase the hypotensive activities of Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Benmoxin.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Dipivefrin.Approved
DisopyramideBenmoxin may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Benmoxin is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideBenmoxin may increase the hypotensive activities of Dorzolamide.Approved
DosulepinBenmoxin may increase the serotonergic activities of Dosulepin.Approved
DoxapramBenmoxin may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinBenmoxin may increase the hypotensive activities of Doxazosin.Approved
DoxepinBenmoxin may increase the serotonergic activities of Doxepin.Approved
DoxylamineBenmoxin may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Benmoxin.Experimental
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Benmoxin.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Benmoxin is combined with Droxidopa.Approved, Investigational
DulaglutideBenmoxin may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineBenmoxin may increase the serotonergic activities of Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Benmoxin.Experimental, Illicit
EfonidipineBenmoxin may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Benmoxin.Approved, Investigational
EmpagliflozinBenmoxin may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilBenmoxin may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatBenmoxin may increase the hypotensive activities of Enalaprilat.Approved
EndralazineBenmoxin may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Benmoxin.Approved, Investigational
EpanololBenmoxin may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Benmoxin is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineBenmoxin may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolBenmoxin may increase the hypotensive activities of Epoprostenol.Approved
EprosartanBenmoxin may increase the hypotensive activities of Eprosartan.Approved
ErgotamineBenmoxin may increase the hypertensive activities of Ergotamine.Approved
EscitalopramBenmoxin may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapineBenmoxin may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Benmoxin.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Benmoxin.Approved, Illicit
EtoperidoneBenmoxin may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Benmoxin.Illicit, Vet Approved
ExenatideBenmoxin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineBenmoxin may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamBenmoxin may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Fenoterol.Approved, Investigational
FentanylFentanyl may increase the serotonergic activities of Benmoxin.Approved, Illicit, Investigational, Vet Approved
Ferulic acidBenmoxin may increase the hypotensive activities of Ferulic acid.Experimental
FluoxetineBenmoxin may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluvoxamineBenmoxin may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Formoterol.Approved, Investigational
FosinoprilBenmoxin may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Benmoxin.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Benmoxin.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Benmoxin.Experimental
GliclazideBenmoxin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBenmoxin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBenmoxin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideBenmoxin may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzBenmoxin may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelBenmoxin may increase the hypotensive activities of Guanadrel.Approved
GuanazodineBenmoxin may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineBenmoxin may increase the hypotensive activities of Guanethidine.Approved
GuanfacineBenmoxin may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorBenmoxin may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzBenmoxin may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanBenmoxin may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypertensive activities of Benmoxin.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Benmoxin.Approved, Illicit, Investigational
HexamethoniumBenmoxin may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineHydracarbazine may increase the hypertensive activities of Benmoxin.Experimental
HydralazineBenmoxin may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideBenmoxin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Benmoxin is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideBenmoxin may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Benmoxin is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineBenmoxin may increase the hypertensive activities of Hydroxyamphetamine.Approved
ImidaprilBenmoxin may increase the hypotensive activities of Imidapril.Investigational
ImipramineBenmoxin may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Indacaterol.Approved
IndalpineBenmoxin may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideBenmoxin may increase the hypotensive activities of Indapamide.Approved
IndenololBenmoxin may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminBenmoxin may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartBenmoxin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirBenmoxin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineBenmoxin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineBenmoxin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanBenmoxin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproBenmoxin may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Benmoxin.Approved
IprindoleBenmoxin may increase the serotonergic activities of Iprindole.Experimental
IproclozideBenmoxin may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Benmoxin.Withdrawn
IrbesartanBenmoxin may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Benmoxin.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Benmoxin is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Isoprenaline.Approved
IsradipineBenmoxin may increase the hypotensive activities of Isradipine.Approved
KetanserinBenmoxin may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Benmoxin.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Benmoxin.Approved, Nutraceutical, Withdrawn
LabetalolBenmoxin may increase the hypotensive activities of Labetalol.Approved
LacidipineBenmoxin may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostBenmoxin may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineBenmoxin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Benmoxin.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Benmoxin.Approved, Investigational
LevomilnacipranBenmoxin may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinBenmoxin may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Benmoxin.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Levosalbutamol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Benmoxin is combined with Linezolid.Approved, Investigational
LinsidomineBenmoxin may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideBenmoxin may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineBenmoxin may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilBenmoxin may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Benmoxin.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Benmoxin is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Benmoxin.Illicit
LofepramineBenmoxin may increase the serotonergic activities of Lofepramine.Experimental
LofexidineBenmoxin may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanBenmoxin may increase the hypotensive activities of Losartan.Approved
MacitentanBenmoxin may increase the hypotensive activities of Macitentan.Approved
ManidipineBenmoxin may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Benmoxin.Approved
MebanazineBenmoxin may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineBenmoxin may increase the hypotensive activities of Mecamylamine.Approved
MecaserminBenmoxin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MephedroneBenmoxin may increase the hypertensive activities of Mephedrone.Investigational
MephentermineBenmoxin may increase the hypertensive activities of Mephentermine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Benmoxin.Experimental
MequitazineBenmoxin may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolBenmoxin may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminBenmoxin may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Benmoxin is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Benmoxin.Approved, Illicit
MethamphetamineBenmoxin may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoserpidineBenmoxin may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineBenmoxin may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Benmoxin.Experimental
MethyldopaThe risk or severity of adverse effects can be increased when Benmoxin is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Benmoxin.Experimental
Methylene blueBenmoxin may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateBenmoxin may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetipranololBenmoxin may increase the hypotensive activities of Metipranolol.Approved
MetolazoneBenmoxin may increase the hypotensive activities of Metolazone.Approved
MetoprololBenmoxin may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineBenmoxin may increase the hypotensive activities of Metyrosine.Approved
MianserinBenmoxin may increase the neurotoxic activities of Mianserin.Approved, Investigational
MibefradilBenmoxin may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineBenmoxin may increase the hypertensive activities of Midodrine.Approved
MidomafetamineBenmoxin may increase the hypertensive activities of Midomafetamine.Experimental, Illicit, Investigational
MifepristoneBenmoxin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolBenmoxin may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranBenmoxin may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Benmoxin.Approved
MinoxidilBenmoxin may increase the hypotensive activities of Minoxidil.Approved
MirtazapineBenmoxin may increase the central neurotoxic activities of Mirtazapine.Approved
MMDABenmoxin may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Benmoxin is combined with Moclobemide.Approved
MoexiprilBenmoxin may increase the hypotensive activities of Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Morphine.Approved, Investigational
MoxonidineBenmoxin may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineBenmoxin may increase the hypotensive activities of Muzolimine.Experimental
NadololBenmoxin may increase the hypotensive activities of Nadolol.Approved
NaftopidilBenmoxin may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Benmoxin.Approved
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Benmoxin.Approved, Investigational
NateglinideBenmoxin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololBenmoxin may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneBenmoxin may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Benmoxin.Withdrawn
NicardipineBenmoxin may increase the hypotensive activities of Nicardipine.Approved
NicorandilBenmoxin may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineBenmoxin may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineBenmoxin may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineBenmoxin may increase the hypotensive activities of Nimodipine.Approved
NisoldipineBenmoxin may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineBenmoxin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideBenmoxin may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineBenmoxin may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Benmoxin.Approved, Illicit
NortriptylineBenmoxin may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinBenmoxin may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Olanzapine.Approved, Investigational
OlmesartanBenmoxin may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Olodaterol.Approved
OmapatrilatBenmoxin may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolBenmoxin may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Benmoxin.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Orciprenaline.Approved
OxprenololBenmoxin may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Benmoxin is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Benmoxin.Approved, Investigational, Vet Approved
PargylineBenmoxin may increase the hypotensive activities of Pargyline.Approved
ParoxetineBenmoxin may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololBenmoxin may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineBenmoxin may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Benmoxin.Approved, Vet Approved
PentoliniumBenmoxin may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Benmoxin.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilBenmoxin may increase the hypotensive activities of Perindopril.Approved
PethidineBenmoxin may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Benmoxin.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Benmoxin.Approved
PheniprazineBenmoxin may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Benmoxin.Experimental
PhenoxybenzamineBenmoxin may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineBenmoxin may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineBenmoxin may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineBenmoxin may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineBenmoxin may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Benmoxin.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Benmoxin.Investigational
PinacidilBenmoxin may increase the hypotensive activities of Pinacidil.Withdrawn
PindololBenmoxin may increase the hypotensive activities of Pindolol.Approved
PioglitazoneBenmoxin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Benmoxin.Investigational
PirlindolePirlindole may increase the hypertensive activities of Benmoxin.Approved
PivhydrazineBenmoxin may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenBenmoxin may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorBenmoxin may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideBenmoxin may increase the hypotensive activities of Polythiazide.Approved
PramlintideBenmoxin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinBenmoxin may increase the hypotensive activities of Prazosin.Approved
ProcarbazineProcarbazine may increase the hypertensive activities of Benmoxin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Procaterol.Approved, Investigational
PropranololBenmoxin may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineBenmoxin may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Benmoxin.Investigational
PseudoephedrineBenmoxin may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilBenmoxin may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineBenmoxin may increase the hypoglycemic activities of Quinine.Approved
RamiprilBenmoxin may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Benmoxin.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Benmoxin.Approved
RemikirenBenmoxin may increase the hypotensive activities of Remikiren.Approved
RepaglinideBenmoxin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineBenmoxin may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Reserpine.Approved, Investigational
RilmenidineBenmoxin may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatBenmoxin may increase the hypotensive activities of Riociguat.Approved
RitobegronBenmoxin may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Ritodrine.Approved, Investigational
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Benmoxin.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Benmoxin.Approved, Investigational
RosiglitazoneBenmoxin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineBenmoxin may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Salmeterol.Approved
SaprisartanBenmoxin may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinBenmoxin may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Benmoxin.Approved, Investigational, Vet Approved
SelexipagBenmoxin may increase the hypotensive activities of Selexipag.Approved
SertralineBenmoxin may increase the serotonergic activities of Sertraline.Approved
SitagliptinBenmoxin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanBenmoxin may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilBenmoxin may increase the hypotensive activities of Spirapril.Approved
SufentanilSufentanil may increase the serotonergic activities of Benmoxin.Approved, Investigational
SulfadiazineBenmoxin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleBenmoxin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleBenmoxin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Benmoxin.Approved, Investigational
SunitinibBenmoxin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololBenmoxin may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Benmoxin.Approved
TelmisartanBenmoxin may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilBenmoxin may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Terbutaline.Approved
TerlipressinBenmoxin may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Benmoxin.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Benmoxin.Approved
TetrahydropalmatineBenmoxin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineBenmoxin may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineBenmoxin may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Benmoxin.Approved, Investigational
TiboloneBenmoxin may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenBenmoxin may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Benmoxin.Experimental
TimololBenmoxin may increase the hypotensive activities of Timolol.Approved
TolazamideBenmoxin may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineBenmoxin may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideBenmoxin may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Benmoxin.Approved, Withdrawn
TolonidineBenmoxin may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Benmoxin.Approved
TorasemideBenmoxin may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Benmoxin.Approved, Investigational
TrandolaprilBenmoxin may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Benmoxin.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Benmoxin.Approved
TravoprostBenmoxin may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Benmoxin is combined with Trazodone.Approved, Investigational
TreprostinilBenmoxin may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideBenmoxin may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinBenmoxin may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanBenmoxin may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineBenmoxin may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneBenmoxin may increase the hypotensive activities of Unoprostone.Approved
UrapidilBenmoxin may increase the hypotensive activities of Urapidil.Investigational
ValsartanBenmoxin may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineBenmoxin may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Benmoxin.Approved
VincamineBenmoxin may increase the hypotensive activities of Vincamine.Experimental
VinpocetineBenmoxin may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Benmoxin.Approved
XipamideBenmoxin may increase the hypotensive activities of Xipamide.Experimental
XylometazolineBenmoxin may increase the hypotensive activities of Xylometazoline.Approved
ZimelidineBenmoxin may increase the serotonergic activities of Zimelidine.Withdrawn
ZofenoprilBenmoxin may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Benmoxin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
71671
PubChem Substance
310265149
ChemSpider
64728
ChEBI
134978
ChEMBL
CHEMBL1877495
Wikipedia
Benmoxin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0289 mg/mLALOGPS
logP2.26ALOGPS
logP2.89ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)14.47ChemAxon
pKa (Strongest Basic)3.32ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area41.13 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity82.98 m3·mol-1ChemAxon
Polarizability26.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acids and derivatives. These are organic compounds containing a carboxylic acid substituent attached to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acids and derivatives
Alternative Parents
Benzoyl derivatives / Carboxylic acid hydrazides / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Benzoic acid or derivatives / Benzoyl / Carboxylic acid hydrazide / Carboxylic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 16:19 / Updated on December 01, 2017 16:14